Skip to main content

Table 1 Characteristics of patients aged less than 40 years with immunohistochemistry results

From: Impact of established prognostic factors and molecular subtype in very young breast cancer patients: pooled analysis of four EORTC randomized controlled trials

Characteristic

All patients

(N= 549)

Node negative patients (N= 341)

 

No. of Patients

%

No. of Patients

%

Age, years

    

Median (range)

36.8 (23 to 40)

36.8 (25 to 40)

Age distribution

    

   ≥ 30 years

57

10

40

12

   31 to 35 years

178

32

107

31

   35 to 40 years

314

58

194

57

Pathological tumor size

    

   T1a and T1b

37

7

30

10

   T1c

296

60

241

64

   T2

158

32

82

26

   T3

6

1

2

1

   Missing

32

 

26

 

Pathological nodal status

    

   Negative

341

63

341

100

   Positive

204

37

0

0

   Missing

4

   

Surgery

    

   Breast conserving

446

81

299

88

   Mastectomy

102

19

42

12

   Missing

1

 

0

 

Adjuvant chemotherapy1

    

   No

326

60

304

89

   Yes

221

40

37

11

   Missing

2

 

0

 

ER status

    

   Positive

310

66

115

41

   Negative

158

34

165

59

   Missing

81

 

61

 

PgR status

    

   Positive

223

48

141

51

   Negative

241

52

136

49

   Missing

85

 

64

 

Tumor type

    

   Ductal

497

96

306

96

   Lobular

17

3

10

3

   Other

5

1

4

1

   Missing

30

 

21

 

Histological grade

    

   I

76

15

54

17

   II

165

32

93

29

   III

276

53

172

54

   Missing

32

 

22

 

Lymphangio invasion

    

   None

357

69

243

76

   1-5 vessels

86

17

49

15

   > 5 vessels

76

14

27

9

   Missing

30

 

22

 

HER2 status

    

   Negative

346

74

216

63

   Positive

119

26

64

19

   Missing

84

 

61

 

P53 status

    

   Negative

331

71

198

72

   Positive

133

29

78

28

   Missing

85

 

65

 

Molecular subtype

    

   Luminal A

154

34

79

29

   Luminal B

157

34

86

32

   HER-2

35

8

90

34

   Basal (triple-negative)

111

24

14

5

   Missing

92

 

72

 
  1. 1 EORTC trial 10854 randomized between one course of peri-operative chemotherapy which was not considered as prolonged chemotherapy.
  2. Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PgR, progesterone receptor.